Retatrutide vs Ozempic is the comparison doctors and patients have been waiting for, and on 28 October 2026 Eli Lilly announced the first head-to-head result: in the TRANSCEND-T2D-2 trial, retatrutide helped adults with type 2 diabetes lose more than twice as much weight as Ozempic over 80 weeks. The result, trending per news coverage after Reuters and other outlets reported Lilly's announcement on Wednesday, does not mean retatrutide is available yet. It is still an investigational drug, it has not been approved by regulators, and the numbers come from topline results announced by the company that makes it.
Even with those limits, the trial matters because it is a direct test rather than a comparison across different studies. Both groups were in the same trial, followed for the same 80 weeks, and measured on the same outcomes: blood sugar control, weight loss, and safety. This article explains what the retatrutide vs Ozempic trial found, how retatrutide works, what side effects were reported, and what still has to happen before anyone could be prescribed it.
Retatrutide vs Ozempic: The Head-to-Head Trial Results in Numbers
TRANSCEND-T2D-2 enrolled 1,298 adults with type 2 diabetes whose blood sugar was not adequately controlled with metformin, with or without an SGLT2 inhibitor, according to Lilly's trial summary reported by Kalkine and Securities.io. Participants were assigned to retatrutide 9 mg, retatrutide 12 mg, or injectable Ozempic 2 mg, given once a week. The trial's main goal was to show that retatrutide 12 mg was at least as good as Ozempic 2 mg at lowering A1C, a measure of average blood sugar over time. Lilly said retatrutide met that goal and also did better on key secondary measures, including weight loss.
After 80 weeks, starting from an average A1C of 8.3%, both retatrutide doses lowered A1C by an average of 2.2 percentage points, compared with 1.8 percentage points for Ozempic 2 mg. The difference in blood sugar control was real but modest: 0.4 percentage points. The difference in weight was much larger. People taking retatrutide 9 mg lost an average of 44.3 pounds (19.5% of body weight), and people taking 12 mg lost an average of 47.4 pounds (20.9%). People taking Ozempic lost an average of 20.9 pounds (9.4%). In other words, the average weight loss on retatrutide was more than double the average on Ozempic in this trial.
Lilly also said retatrutide delivered greater improvements than Ozempic across certain cardiovascular risk factors, including non-HDL cholesterol, triglycerides, and systolic blood pressure. The company did not publish the full numerical details for those measures in the topline announcement reported on 28 October, so readers should treat that part of the claim as summary-level until fuller results are published. The headline weight and A1C figures are the numbers Lilly put on the record for this trial.
Context helps here. Weight loss in drug trials is usually smaller in people with type 2 diabetes than in people without diabetes, a pattern noted in reporting on this class of drugs. That makes the roughly 20% average loss in TRANSCEND-T2D-2 notable, but it does not make it typical for every person. Trial averages hide wide variation: some participants lose much more than the average, some lose much less, and some stop treatment because of side effects. Averages describe a group, not a promise for an individual.
What Is Retatrutide? Why the Triple-G Label Matters
Retatrutide is a once-weekly injection being developed by Eli Lilly. It is sometimes called a triple-G drug because it activates three hormone receptors at once: GLP-1, GIP, and glucagon. Ozempic, made by Novo Nordisk from semaglutide, activates only the GLP-1 receptor. Lilly's Mounjaro and Zepbound, made from tirzepatide, activate two: GLP-1 and GIP. Retatrutide adds the third, glucagon, which researchers believe may increase energy use as well as helping with appetite and blood sugar control. That three-way action is the main explanation Lilly and independent commentators give for why retatrutide has produced larger average weight loss than earlier drugs in its trial programme.
The evidence has built up through a programme Lilly calls TRIUMPH, plus the TRANSCEND head-to-head studies. Earlier Phase 3 results reported before this announcement included an average loss of 28.3% of body weight over 80 weeks on the 12 mg dose in TRIUMPH-1, a trial in adults with obesity or overweight without diabetes, compared with 2.2% on placebo. In TRIUMPH-2, in adults with type 2 diabetes, the 12 mg dose produced about 20.8% average weight loss at 80 weeks in peer-reviewed reporting. The new TRANSCEND-T2D-2 result fits that pattern: strong weight loss, with a smaller percentage in diabetes than in obesity without diabetes, and a direct win over Ozempic on the same trial's terms.
None of that makes retatrutide a stronger drug for every patient. Dose, tolerability, other health conditions, cost, and access all matter in real prescribing, and none of those can be read off a single trial average. The head-to-head result answers one question, how did retatrutide compare with Ozempic 2 mg in this trial, not the broader question of which treatment is right for a particular person.
Retatrutide vs Ozempic: How the Trial Design Shapes the Result
One detail matters when reading the retatrutide vs Ozempic comparison. Lilly said it used Ozempic 2 mg as the comparator because that is the highest approved dose of injectable Ozempic available. That is a fair and standard choice for a head-to-head trial, but it also means the comparison is against Ozempic at its approved ceiling, not against every semaglutide dose or formulation used in practice, and not against tirzepatide. Readers should not read the result as proof that retatrutide beats every existing diabetes or weight-loss drug. It beat the specific comparator, at the specific dose, in this specific trial population, over 80 weeks.
The trial also tested retatrutide at 9 mg and 12 mg, doses that are investigational and have no approved equivalent yet. Both doses produced similar A1C reductions, while the higher dose produced slightly more weight loss: 47.4 pounds against 44.3 pounds on average. That dose-response pattern, more weight loss at the higher dose, with more side-effect-related discontinuations, described below, is common in this drug class and is one reason dose increases in these treatments are usually gradual.
Finally, topline results are company summaries, not the full peer-reviewed paper. Lilly said TRANSCEND-T2D-2 was the sixth Phase 3 trial in which retatrutide delivered strong efficacy, according to Securities.io's summary of the announcement. Fuller data, including breakdowns by subgroup, longer-term follow-up, and independent peer review, will be needed before doctors can judge how durable the benefit is and who benefits most.
Side Effects and Safety: What the Trial Reported
In TRANSCEND-T2D-2, treatment discontinuation because of adverse events was 4.8% on retatrutide 9 mg and 7.9% on retatrutide 12 mg, compared with 2.7% on Ozempic 2 mg, Lilly reported. Most adverse events were described as mild to moderate, and gastrointestinal effects were the most common pattern, as with other drugs in this class. In other retatrutide trials, nausea, diarrhoea, constipation, and vomiting were the most frequently reported effects, mainly while the dose was being increased.
One side effect deserves a clear explanation because it is less familiar. Dysesthesia, an unusual skin sensation such as tingling, burning, or heightened sensitivity, has been reported in retatrutide trials and linked by researchers to glucagon receptor activity. In TRIUMPH-1, one summary put nausea at about 42% of people on the 12 mg dose, diarrhoea at 32%, constipation at 26%, and vomiting at 25%, with dysesthesia reported in about 12.5%; other summaries put the skin-sensation figure higher in different trials and doses. The exact rate varies by trial, dose, and how the effect was counted, so a single percentage should not be treated as a fixed risk for any individual. The consistent point across trials is that skin tingling is a recognised retatrutide signal that doctors will watch, alongside gut effects and heart-rate changes reported in earlier studies.
That safety picture is also why unapproved products sold online as retatrutide are a risk. Retatrutide is not approved, so anything sold online or as a research peptide has not been reviewed for safety, strength, or sterility, and regulators have warned against such sales. The nationwide recall of GLP-1 injections over a sterility concern in October 2026 is a reminder of what can go wrong when injectable products are made outside approved controls. This article is general information only, not medical advice: anyone considering a diabetes or weight-loss treatment should discuss approved options with their own clinician.
When Could Retatrutide Be Available? The FDA Timeline Explained
Retatrutide remains investigational and has not been approved by the US Food and Drug Administration or any other regulator, according to every summary of the 28 October announcement. Lilly plans to submit an application to the FDA in the first quarter of 2027, with obesity as the first indication sought, according to reporting on the company's plans. A submission is not an approval: regulators review the full data, may ask for more information, and set the final label, including who the drug is for and what warnings it carries. No approval date can be promised from a filing plan alone.
Lilly has also said it plans to seek approval for other conditions supported by its Phase 3 programme, including obstructive sleep apnoea and knee osteoarthritis pain, with further studies under way in areas such as cardiovascular and kidney outcomes and liver disease. Those are research plans, not approved uses. Until a regulator approves retatrutide for a specific use, it cannot legally be prescribed or sold for that use outside clinical trials and any narrow early-access route the company operates.
For readers in the United Kingdom, Canada, Australia, and other markets, the same caution applies in local form: a US filing plan does not set a timeline elsewhere, and each regulator makes its own decision on its own timetable. Price, supply, and eligibility rules, if the drug is ever approved, have not been announced and cannot be inferred from trial results.
What the Result Means, and What Happens Next
For people living with type 2 diabetes, the practical meaning is narrower than headlines suggest. Better average blood sugar control combined with substantial average weight loss could matter a great deal, because weight and blood sugar interact and weight loss can improve several risk factors at once. But prescribing decisions also weigh tolerability, heart and kidney history, other medicines, pregnancy plans, cost, and personal preference. Ozempic remains an approved, widely prescribed treatment: Investor's Business Daily reported that it brought in more than 20 billion dollars in sales last year, and nothing in the TRANSCEND-T2D-2 announcement changes its approved status. The trial adds a future option to watch, it does not remove a current one.
For the wider drug race, the result sharpens the contest between Lilly and Novo Nordisk and shows why other companies are investing in the same field, including Roche's October 2026 deal worth up to 1.16 billion dollars for an obesity treatment programme. Investors reacted modestly on the day, with Novo Nordisk shares slipping in morning trading while Lilly shares edged up, according to Investor's Business Daily, but share moves on one announcement say little about whether a drug will help patients or pass regulatory review.
What happens next is evidence, then regulation. Fuller TRANSCEND-T2D-2 results should be published and peer-reviewed, Lilly should file for approval in early 2027 as planned, and longer outcome trials will test whether the weight and blood sugar gains translate into fewer heart, kidney, and other complications over years. Until then, the honest summary is this: retatrutide vs Ozempic, tested head to head in 1,298 people with type 2 diabetes over 80 weeks, produced a clear win on average weight loss, a modest win on average blood sugar, and a higher rate of stopping treatment because of side effects. It is a promising investigational drug, not an available treatment, and anyone interested in it should talk to a clinician about approved options that exist today rather than seeking unapproved products online.
Sources: Reuters reporting on Lilly's TRANSCEND-T2D-2 announcement, 28 October 2026, as republished by SRN News and other outlets; Kalkine summary of the TRANSCEND-T2D-2 topline results, 28 October 2026; Securities.io summary of the Phase 3 head-to-head trial, 28 October 2026; Investor's Business Daily reporting on the head-to-head result and market reaction, 28 October 2026; Medical Daily reporting on the peer-reviewed TRIUMPH-2 results in The Lancet, 2 October 2026; and earlier trial summaries of TRIUMPH-1 side effects and the planned first-quarter 2027 FDA submission. Figures are Lilly's announced topline results and have not yet been published in full peer-reviewed form for this head-to-head trial.